[1]张翔宇,马义辉,张庭保,等.血小板聚集率检测在颅内动脉瘤介入治疗中的价值[J].中国临床神经外科杂志,2023,28(01):1-4.[doi:10.13798/j.issn.1009-153X.2023.01.001]
　ZHANG Xiang-yu,MA Yi-hui,ZHANG Ting-bao,et al.Value of platelet aggregation rate detection in inter-ventional treatment for patients with unruptured intra-cranial aneurysms[J].,2023,28(01):1-4.[doi:10.13798/j.issn.1009-153X.2023.01.001]
点击复制

血小板聚集率检测在颅内动脉瘤介入治疗中的价值()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年01期
页码:
1-4
栏目:
论著
出版日期:
2023-01-25

文章信息/Info

Title:
Value of platelet aggregation rate detection in inter-ventional treatment for patients with unruptured intra-cranial aneurysms
文章编号:
1009-153X（2023）01-0001-04
作者:
张翔宇; 马义辉; 张庭保; 李正伟; 陈劲草
430071武汉，武汉大学中南医院神经外科（张翔宇、马义辉、张庭保、李正伟、陈劲草）
Author(s):
ZHANG Xiang-yu;  MA Yi-hui;  ZHANG Ting-bao;  LI Zheng-wei;  CHEN Jin-cao
Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
关键词:
颅内动脉瘤; 未破裂动脉瘤; 支架辅助栓塞; 出血性并发症; 缺血性并发症; 血小板聚集率
Keywords:
Unruptured intracranial aneurysms;  Stent-assisted embolization;  Platelet aggregation rate;  Hemorrhagic complications;  Ischemic complications
分类号:
R743.9;R815.2
DOI:
10.13798/j.issn.1009-153X.2023.01.001
文献标志码:
A
摘要:
目的 探讨血小板聚集率检测在颅内未破裂动脉瘤介入治疗中的价值。方法 回顾性分析2020年1月至2022年4月使用支架辅助栓塞治疗的215例颅内未破裂动脉瘤的临床资料。术前1 d检测血小板聚集率，术后复查CT、MRI评估出血性和缺血性并发症。结果 术后发生缺血性并发症16例（7.4%），出血性并发症14例（6.5%）。术前血小板聚集率≤15%的病人出血性并发症发生率（11.8%）较血小板聚集率>15%的病人（3.1%）明显增高（P<0.05）。而血小板聚集率与缺血性并发症无明显关系（P>0.05）。结论 抗血小板药物的使用降低了支架辅助栓塞颅内动脉瘤病人的缺血风险，并且使术前血小板聚集率维持在较低水平，而术前血小板聚集率过低可能是发生出血性并发症的危险因素。当血小板聚集率≤15%时，需警惕出血风险。
Abstract:
Objective To investigate the value of platelet aggregation rate detection in interventional treatment for patients with unruptured intracranial aneurysms. Methods The clinical data of 215 patients with unruptured intracranial aneurysms treated with stent-assisted embolization from January 2020 to April 2022 were retrospectively analyzed. The platelet aggregation rate was detected 1 day before surgery. CT or MRI was used to evaluate hemorrhagic and ischemic complications after the surgery. Results Ischemic complications occurred in 16 patients (7.4%) and hemorrhagic complications in 14 patients (6.5%). The incidence of hemorrhagic complications in patients with platelet aggregation rate ≤15% (11.8%) was significantly higher than that (3.1%) in patients with platelet aggregation rate >15% (P<0.05). There was no significant relationship between platelet aggregation rate and ischemic complications (P>0.05). Conclusions Antiplatelet drugs can maintain the preoperative platelet aggregation rate at a low level and reduce the risk of ischemic complications in patients with unruptured intracranial aneurysms after stent-assisted embolization. However, a low preoperative platelet aggregation rate may be a risk factor for hemorrhagic complications. The platelet aggregation rate ≤15% is a warning value for the bleeding.

参考文献/References:

[1]中国医师协会神经介入专业委员会中国颅内动脉瘤计划研究组. 中国颅内未破裂动脉瘤诊疗指南2021[J]. 中国脑血管病杂志，2021，18（9）：634-664.
[2]姚益峰，朱卫兵，王　军. PED治疗椎-基底动脉未破裂夹层动脉瘤的安全性和有效性[J]. 中国临床神经外科杂志，2022，27（9）：770-772.
[3]梁甲宁，张　广，刘彬冰，等. 颅内动脉瘤LVIS支架辅助栓塞后中长期随访分析[J]. 中国临床神经外科杂志，2018，23（3）：152-154.
[4]Kim KS, Fraser JF, Grupke S, et al. Management of antiplatelet therapy in patients undergoing neuroendovascular procedures [J]. J Neurosurg, 2018, 129(4): 890-905.
[5]Yamada NK, Cross DT, Pilgram TK, et al. Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms [J]. AJNR Am J Neuroradiol, 2007, 28(9): 1778-1782.
[6]Pearce S, Maingard JT, KuanKok H, et al. Antiplatelet drugs for neurointerventions: Part 2--clinical applications [J]. Clin Neuroradiol, 2021, 31(3): 545-558.
[7]Le Quellec S, Bordet JC, Negrier C, et al. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response: a review of the literature [J]. Thromb Haemost, 2016, 116(4): 638-650.
[8]Lee CR, Luzum JA, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update [J]. Clin Pharmacol Ther, 2022, 5(112): 959-967.
[9]Gurbel PA, BlidenKP, Etherington A, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients [J]. Thromb Res, 2007, 121(1): 107-115.
[10]Park KY, Ozaki T, Kostynskyy A, et al. Ticagrelor versus clopidogrel in the dual antiplatelet regimen for intracranial stenting or flow-diverter treatment for unruptured cerebral aneurysms: a single-center cohort study [J]. AJNR Am J Neuroradiol, 2021, 42(9): 1638-1644.
[11]Bhatia KD, Kortman H, Orru E, et al. Periprocedural complications of second-generation flow diverter treatment using Pipeline Flex for unruptured intracranial aneurysms: a systematic review and meta-analysis [J]. J Neurointerv Surg, 2019, 11(8): 817-824.
[12]Xia PF, Huang YM, Chen G. The effect of ticagrelor for endovascular intervention of intracranial aneurysm patients with or without clopidogrel resistant--a meta-analysis [J]. Brain Sci, 2022, 8(12): 1077.
[13]Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding [J]. J Am Coll Cardiol, 2013, 62(24): 2261-2273.
[14]Kan I, Ishibashi T, Sakuta K, et al. Preoperative light transmission aggregometry values predict for thromboembolic complications after stent-assisted coil embolization [J]. World Neurosurg, 2020, 134: e731-e738.
[15]Breet NJ, van WerkumJW, BoumanHJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation [J]. JAMA, 2010, 303(8): 754-762.

相似文献/References:

[1]曾　春　张施远　蒋永明.复合手术与常规夹闭术治疗颈内动脉后交通动脉破裂动脉瘤的疗效对比研究[J].中国临床神经外科杂志,2016,(05):257.[doi:10.13798/j.issn.1009-153X.2016.05.001]
　ZENG Chun,ZHANG Shi-yuan,JIANG Yong-ming.Analysis of the effects of hybrid surgery on posterior communicating artery aneurysms: a comparison with conventional craniotomy[J].,2016,(01):257.[doi:10.13798/j.issn.1009-153X.2016.05.001]
[2]周有东　敖祥生　刘汉东　王志勇　朱耀祖　周达全.支架辅助弹簧圈和单纯弹簧圈栓塞治疗颅内动脉瘤疗效及安全性的Meta分析[J].中国临床神经外科杂志,2016,(05):274.[doi:10.13798/j.issn.1009-153X.2016.05.006]
　ZHOU You-dong,AO Xiang-sheng,LIU Han-dong,et al.A mata-analysis of curative effects of stent-assisted coiling and simple coiling on intracranial aneurysms and their safety[J].,2016,(01):274.[doi:10.13798/j.issn.1009-153X.2016.05.006]
[3]赵　平　王雄伟　汪　雷　马金阳.显微手术和血管内栓塞术治疗颅内动脉瘤的疗效分析[J].中国临床神经外科杂志,2016,(05):281.[doi:10.13798/j.issn.1009-153X.2016.05.008]
　ZHAO Ping,WANG Xiong-wei,WANG Lei,et al.Effect of endovascular treatment on intracranial aneurysms: a comparison with microsurgery[J].,2016,(01):281.[doi:10.13798/j.issn.1009-153X.2016.05.008]
[4]李朝晖　王玉贵　张孟超 综述　赵兴利 审校.CT灌注成像在动脉瘤性蛛网膜下腔出血中的 临床应用进展[J].中国临床神经外科杂志,2016,(05):313.[doi:10.13798/j.issn.1009-153X.2016.05.021]
[5]刘福德　邓剑平　张　涛　陈　虎　李　帅　王俭博　曲友直　赵振伟.椎-基底动脉夹层动脉瘤的血管内治疗（附48例分析）[J].中国临床神经外科杂志,2016,(06):353.[doi:10.13798/j.issn.1009-153X.2016.06.011]
　LIU Fu-de,DENG Jian-ping,ZHANG Tao,et al.Endovascular treatment of vertebrobasilar artery dissecting aneurysms (report of 48 cases)[J].,2016,(01):353.[doi:10.13798/j.issn.1009-153X.2016.06.011]
[6]吴有志　罗良生　张　健　陈　骅　吴　鸣　刘　振　史　岩.前循环破裂动脉瘤伴脑内血肿的 早期显微手术治疗[J].中国临床神经外科杂志,2016,(06):376.[doi:10.13798/j.issn.1009-153X.2016.06.020]
[7]潘　力　刘　鹏　秦　杰　杨　柳　安学峰　吴　虓　杨　铭　徐国政　马廉亭.Y型支架辅助技术在颅内动脉分叉部宽颈动脉瘤治疗中的应用[J].中国临床神经外科杂志,2016,(07):394.[doi:10.13798/j.issn.1009-153X.2016.07.002]
　PAN Li,LIU Peng,QIN Jie,et al.Application of Y -configuration stent technique to treatment of intracranial wide-neck bifurcation aneurysms[J].,2016,(01):394.[doi:10.13798/j.issn.1009-153X.2016.07.002]
[8]周　量　刘　丛　张昌伟.早期栓塞术治疗动脉瘤性蛛网膜下腔出血的疗效[J].中国临床神经外科杂志,2016,(07):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
　ZHOU Liang,LIU Cong,ZHANG Chang-wei..Curative effect of early endovascular embolization on patients with ruptured intracranial aneurysms[J].,2016,(01):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
[9]张　莹　荆林凯　张倩倩　刘　健　张义森　王　坤　穆士卿　杨新健.颈内动脉后交通动脉小动脉瘤破裂危险因素分析[J].中国临床神经外科杂志,2016,(03):138.[doi:10.13798/j.issn.1009-153X.2016.03.002]
　ZHANG Ying,JING Lin-kai,ZHANG Qian-qian,et al.Analysis of risk factors related to rupture of small (diameter ≤5 mm) posterior communicating artery aneurysms[J].,2016,(01):138.[doi:10.13798/j.issn.1009-153X.2016.03.002]
[10]朱作磊 综述　罗良生 审校.动脉瘤性蛛网膜下腔出血的预后相关因素研究进展[J].中国临床神经外科杂志,2016,(03):183.[doi:10.13798/j.issn.1009-153X.2016.03.020]
[11]田　其　杨锐博　韩守孟　王军民　陈　刚　陈谦学　李明昌.Tubridge血流导向装置治疗颅内大型未破动脉瘤[J].中国临床神经外科杂志,2021,26(06):414.[doi:10.13798/j.issn.1009-153X.2021.06.004]
　TIAN Qi,YANG Rui-bo,HAN Shou-men,et al.Safety and efficacy of Tubridge flow-diverter devices for patients with large unruptured intracranial aneurysm (report of 8 cases)[J].,2021,26(01):414.[doi:10.13798/j.issn.1009-153X.2021.06.004]
[12]刘博,袁浩,尤延辉.直接暴露颈动脉穿刺栓塞治疗老年前循环未破裂动脉瘤20例[J].中国临床神经外科杂志,2022,27(01):44.[doi:10.13798/j.issn.1009-153X.2022.01.016]
[13]葛慧剑,桂思铭,邓丁伟,等.颅内未破裂动脉瘤Pipeline栓塞装置置入术后支架内狭窄的危险因素[J].中国临床神经外科杂志,2023,28(07):429.[doi:10.13798/j.issn.1009-153X.2023.07.004]
　GE Hui-jian,GUI Si-ming,DENG Ding-wei,et al.Risk factors for in-stent stenosis in patients with unruptured intracranial aneurysms after Pipeline embolization device implantation[J].,2023,28(01):429.[doi:10.13798/j.issn.1009-153X.2023.07.004]

备注/Memo

备注/Memo:
（2022-11-16收稿，2022-12-28修回）
通讯作者：陈劲草，E-mail：chenjincao2012@163.com
更新日期/Last Update: 2022-02-28